INTENSITY THERAPEUTICS, INC.

INTSdata completeness 63%4 fiscal years on file

Data notes: no data for concept 'revenue'; no data for concept 'capex'; no data for concept 'totalDebt'; no data for concept 'pretaxIncome'

The thesis, from the filings

INTENSITY THERAPEUTICS, INC. earns about -245% on equity, and has bought back 60% of its shares over 4 years. The cash-flow models don't apply cleanly here — the ledger says why below.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.

i. The business — what you’d actually own

Figure	FY 2022	FY 2023	FY 2024	FY 2025
Revenue	—	—	—	—
Net income	−$7.58M¹	−$10.5M²	−$16.3M³	−$11.6M³
Operating cash flow	−$5.48M⁴	−$7.21M⁵	−$15.2M⁶	−$9.23M⁶
Capital expenditure	—	—	—	—
Free cash flow (derived)	—	—	—	—
Total debt	—	—	—	—
Cash & equivalents	$1.31M⁷	$8.56M⁸	$2.59M⁹	$11.9M⁹
Diluted shares	3.4M	8.6M	556,279	1.4M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal

If you owned

Net assets behind them

$87.56

your share of equity

Profit it earned you last year

−$85.57

Free cash flow it threw off

—

Debt you’d be carrying

—

10 shares is a claim on $87.56 of net worth that earned you −$85.57 last year.

iii. Is this a good business?

Moat signal · return on equity

-245% avg · 4y

FY22 —FY23 -80%FY24 -558%FY25 -98%

It earned an average -245% on equity over 4 years. Compare that to what it costs to fund the business.

seeing a moat in the numbers →

Management signal · capital allocation

−60% shares · 4y

Share count is down 60% over 4 years — management has been buying back stock, quietly handing owners a bigger slice.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0

DCF · Growth Exit 10Y

not applicable

only 0 years of FCF (need ≥3) — model not applicable

DCF · Growth Exit 5Y

not applicable

only 0 years of FCF (need ≥3) — model not applicable

Earnings Power Value

not applicable

normalized (5y-median) earnings non-positive — EPV undefined

Graham Number

not applicable

diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts

10-K · period ending 2022-12-31 · accession 0001628280-24-011207 (NetIncomeLoss)
10-K · period ending 2023-12-31 · accession 0001567264-25-000010 (NetIncomeLoss)
10-K · period ending 2024-12-31 · accession 0001567264-26-000024 (NetIncomeLoss)
10-K · period ending 2022-12-31 · accession 0001628280-24-011207 (NetCashProvidedByUsedInOperatingActivities)
10-K · period ending 2023-12-31 · accession 0001567264-25-000010 (NetCashProvidedByUsedInOperatingActivities)
10-K · period ending 2024-12-31 · accession 0001567264-26-000024 (NetCashProvidedByUsedInOperatingActivities)
10-K · period ending 2022-12-31 · accession 0001628280-24-011207 (CashAndCashEquivalentsAtCarryingValue)
10-K · period ending 2023-12-31 · accession 0001567264-25-000010 (CashAndCashEquivalentsAtCarryingValue)
10-K · period ending 2024-12-31 · accession 0001567264-26-000024 (CashAndCashEquivalentsAtCarryingValue)